Higher Doses Of Novocure’s TTF Help New Glioblastoma Patients

The first reported analysis demonstrating a patient-level dose response with Novocure’s Tumor Treating Fields therapy is now published. The post-hoc analysis of the EF-14 trial showed higher doses of Tumor Treating Fields improved survival in newly diagnosed glioblastoma patients.

Higher Doses Of Novocure’s TTF Help New Glioblastoma Patients
Novocure's Optune Tumor Treating Fields device • Source: Novocure LTD

[Editor's note: Complete historical information on important medical device trial announcements is available from Informa’s Meddevicetracker. For an archive of previous Medtech Insight articles on medtech clinical trials, visit the Clinical Trials page.]

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D